Jul 29, 2010

Integra LifeSciences Reports Second Quarter 2010 Financial Results

Revenues Increase 8% to $179 Million

PLAINSBORO, N.J., July 29, 2010 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today reported its financial results for the second quarter ending June 30, 2010. Total revenues for the second quarter were $178.6 million, reflecting an increase of $12.9 million, or 8%, over the second quarter of 2009. We present revenues by product category in a table at the end of this press release.

"Our second quarter results reflect strong internal growth," said Stuart Essig, Integra's President and Chief Executive Officer. "We are heading in to the second half of the year with good momentum."

The Company reported GAAP net income of $15.2 million, or $0.50 per diluted share, for the second quarter of 2010, compared to GAAP net income of $11.2 million, or $0.38 per diluted share, for the second quarter of 2009.

Adjusted net income for the second quarter of 2010, computed with the adjustments to GAAP reporting set forth in the attached reconciliation, was $20.9 million, or $0.68 per diluted share, compared to $18.3 million, or $0.62 per diluted share, in the second quarter of 2009.

Integra generated $19.4 million in cash flows from operations and used $5.7 million of cash on capital expenditures in the second quarter of 2010. During the quarter, Integra redeemed the remaining $78 million outstanding on its 2.75% senior convertible notes in cash. Integra drew down $75 million on its credit facility to meet this obligation.

Adjusted EBITDA for the second quarter of 2010, computed with the adjustments to GAAP reporting set forth in the attached reconciliation, was $35.5 million, up 2% from the second quarter last year.

Adjusted EBITDA excluding stock-based compensation, computed with the adjustments to GAAP reporting set forth in the attached reconciliation, was $39.2 million.

Changes in foreign currency exchange rates had a negligible impact on revenues for the quarter.

Outlook for 2010

The Company is reiterating its revenue guidance as well as its GAAP and adjusted earnings per share guidance for the full year 2010. The Company continues to anticipate revenues between $715 million and $735 million. The Company is guiding to GAAP earnings per diluted share of between $1.92 and $2.07 and to adjusted earnings per diluted share of between $2.60 and $2.75. In accordance with our usual practice, expectations for financial performance do not include the impact of acquisitions or other strategic corporate transactions that have not yet closed.

In the future, the Company may record, or expects to record, certain additional revenues, gains, expenses or charges (such as acquisition-related charges, facility consolidation, manufacturing and distribution transfer charges, systems integration charges, non-cash interest expense related to the application of authoritative guidance for convertible debt instruments that may be settled in cash upon conversion ("FSP APB 14-1"), and intangible asset amortization) that it will exclude in the calculation of adjusted EBITDA and adjusted earnings per share for historical periods and in providing adjusted earnings per share guidance.

Conference Call

Integra has scheduled a conference call for 8:30 AM ET on Thursday, July 29, 2010 to discuss financial results for the second quarter 2010 and forward-looking financial guidance. Integra's senior management team will host the conference call, which will be open to all listeners. Additional forward-looking information may be discussed in a question and answer session following the call.

Access to the live call is available by dialing 719-325-2193 and using the passcode 8154044. The call can also be accessed through a webcast via a link provided on the Investor Relations homepage of Integra's website at www.integralife.com. Access to the replay is available through August 12, 2010 by dialing 719-457-0820 and using the passcode 8154044. The webcast will also be archived on the website.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients every year. Our products are used primarily in orthopedics, neurosurgery and general surgery.  Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world. For more information, visit www.integralife.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and reflect the Company's judgment as of the date of this release. Forward-looking statements include, but are not limited to, statements concerning future financial performance, including projections for revenues, GAAP and adjusted net income, GAAP and adjusted earnings per diluted share, stock-based compensation, non-GAAP adjustments such as acquisition-related charges, non-cash interest expense related to the application of FSP APB 14-1, intangible asset amortization, and income tax expense (benefit) related to non-GAAP adjustments. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Such risks and uncertainties include, but are not limited to: the Company's ability to maintain relationships with customers of acquired entities; physicians' willingness to adopt and third-party payors' willingness to provide reimbursement for the Company's recently launched and planned products; the Company's ability to manufacture sufficient quantities of its products to meet its customers' demand; initiatives launched by the Company's competitors; the Company's ability to secure regulatory approval for products in development; fluctuations in hospital spending for capital equipment; the Company's ability to comply with and obtain approvals for products of human origin and comply with recently enacted regulations regarding products containing materials derived from animal sources; difficulties in controlling expenses, including costs to procure and manufacture our products; the impact of changes in management or staff levels; the Company's ability to integrate acquired businesses; the Company's ability to leverage its existing selling organizations and administrative infrastructure; the Company's ability to increase product sales and gross margins, and control non-product costs; the amount and timing of acquisition and integration related costs; the geographic distribution of where the Company generates its taxable income; the effect of legislation effecting healthcare reform in the United States; the timing and amount of share-based awards granted to employees; fluctuations in foreign currency exchange rates; the amount of our convertible notes and bank borrowings outstanding, and the economic, competitive, governmental, technological and other risk factors and uncertainties identified under the heading "Risk Factors" included in Item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2009 and information contained in subsequent filings with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Discussion of Adjusted Financial Measures

In addition to our GAAP results, we provide adjusted revenues, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted EBITDA excluding stock-based compensation, adjusted net income and adjusted earnings per diluted share. Adjusted revenues consist of growth in total revenues excluding the effects of currency exchange rates on the current period's revenues. The various measures of adjusted EBITDA consist of GAAP net income, excluding: (i) depreciation and amortization, (ii) other income (expense), net, (iii) interest income and expense, (iv) income taxes, (v) those operating expenses also excluded from adjusted net income and, as appropriate (vi) stock-based compensation expense. The measure of adjusted net income consists of GAAP net income, excluding: (i) acquisition-related charges; (ii) certain employee termination and related costs; (iii) intangible asset impairment charges; (iv) charges associated with discontinued or withdrawn product lines; (v) systems implementation charges; (vi) facility consolidation, manufacturing and distribution transfer charges; (vii) charges related to restructuring our European subsidiaries; (viii) gains and losses related to the early extinguishment of convertible notes; (ix) non-cash interest expense related to the application of FSP APB 14-1; (x) intangible asset amortization expense; (xi) quarterly adjustments to income tax expense/benefit related to the cumulative impact of changes in estimated tax rates and certain infrequently occurring items; and (xii) the income tax expense/benefit related to these adjustments. The adjusted earnings per diluted share measure is calculated by dividing adjusted net income attributable to diluted shares by diluted weighted average shares outstanding. Reconciliations of GAAP revenues to adjusted revenues for the quarter ended June 30, 2010 and GAAP net income to adjusted EBITDA, adjusted EBITDA excluding stock-based compensation and adjusted net income, and GAAP earnings per diluted share to adjusted earnings per diluted share for the quarters ended June 30, 2010 and 2009 appear in the financial tables in this release.

Integra believes that the presentation of adjusted revenues and the various adjusted EBITDA, adjusted net income, and adjusted earnings per diluted share measures provides important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. For further information regarding why Integra believes that these non-GAAP financial measures provide useful information to investors, the specific manner in which management uses these measures, and some of the limitations associated with the use of these measures, please refer to the Company's Current Report on Form 8-K regarding this earnings press release filed today with the Securities and Exchange Commission. This Current Report on Form 8-K is available on the SEC's website at www.sec.gov or on our website at www.integralife.com.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
 
  
(In thousands, except per share amounts) 
  Three Months Ended
June 30,
  2010 2009
 
Total revenues
$178,595 $165,725
   
Costs and expenses:  
Cost of product revenues 64,464 59,805
Research and development 11,761 10,302
Selling, general and administrative 74,216 68,252
Intangible asset amortization 3,575 3,461
   
Total costs and expenses 154,016 141,820
   
Operating income 24,579 23,905
 
Interest income
 
52
 
134
Interest expense (4,300) (6,174)
Other income (expense), net 763 (481)
   
Income before income taxes 21,094 17,384
   
Income tax expense 5,937 6,159
   
Net income 15,157 11,225
   
Diluted net income per share * $ 0.50 $ 0.38
   
Weighted average common shares
 outstanding for diluted net
 income per share
30,399 29,202
   
* The calculation of earnings per share for common stock shown above excludes the income attributable to the unvested restricted share units from the numerator and excludes the dilutive impact of those units from the denominator.  The authoritative guidance had an insignificant impact (impacts the rounding by $0.01 or less per share) on diluted net income per share for both periods.  

Listed below are the items included in GAAP revenues and GAAP net income that management excludes in computing the adjusted financial measures referred to in the text of this press release and further described under Discussion of Adjusted Financial Measures.

  
Growth in total revenues excluding the effects of currency exchange rates
(In thousands)
 
  
  Three Months Ended
  June 30,
  2010 2009 Change
Integra Orthopedics $ 72,819 $ 65,164 11.7%
Integra NeuroSciences 66,306 61,448 7.9%
Integra Medical Instruments 39,470 39,113 0.9%
Net Sales $178,595 $165,725 7.8%
    
Impact of changes in   
  currency exchange rates 548 -- 
Growth in total revenues   
 excluding the effects of   
 currency exchange rates $179,143 $165,725 8.1%
  
Items included in GAAP net income
(In thousands)
 
  Three Months Ended
June 30,
  2010 2009
   
Acquisition-related charges (a) $640 $1,924
   
Employee termination and related costs (b) -- 196
   
Intangible asset impairment charges (c) * 797 --
   
Charges associated with discontinued or withdrawn
 product lines (d)
-- 246
   
Systems implementation charges (e) 548 --
   
Facility consolidation, manufacturing and
 distribution transfer charges (f)
236 189
   
Loss related to early extinguishment of
 convertible notes (g)
-- 89
   
Non-cash interest expense related to the
 implementation of FSP APB 14-1 (h)
1,888 2,765
   
Intangible asset amortization expense (i) * 4,211 4,866
   
Income tax expense related to
 above adjustments, quarterly adjustments to
 income tax expense related to the
 cumulative impact of changes in estimated tax
 rates and certain infrequently occurring items
 that affected the reported tax rate
(2,593) (3,174)
   
Stock-based compensation expense 3,677 3,971
   
Depreciation expense 4,515 3,601
   
(a) Q2 2010 - $386 recorded in cost of product revenues, $206 in selling general and administrative, and $48 in research and development; Q2 2009 – all recorded in cost of product revenues.
(b) Q2 2009 – all recorded in selling general and administrative.
(c)  Q2 2010 – all recorded in intangible asset amortization.
(d)  Q2 2009 – all recorded in cost of product revenues.
(e)  Q2 2010 - all recorded in selling general and administrative.
(f) All recorded in cost of product revenues.
(g) Q2 2009 – all recorded in other income (expense), net.
(h) All recorded in interest expense.
(i) Q2 2010 – $1,433 recorded in cost of product revenues, and $2,778 in intangible asset amortization; Q2 2009 – $1,405 recorded in cost of product revenues, and $3,461 in intangible asset amortization.
* Intangible asset amortization expense in (i) excludes $797 already mentioned in item (c).
  
   
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
RECONCILIATION OF NON-GAAP ADJUSTMENTS – GAAP NET INCOME TO ADJUSTED EBITDA AND ADJUSTED
EBITDA EXCLUDING STOCK BASED COMPENSATION
(UNAUDITED)
 
 (In thousands) 
  Three Months Ended
June 30,
  2010 2009
   
GAAP net income $15,157 $11,225
Non-GAAP adjustments:  
   
Depreciation and intangible asset amortization
 expense
8,726 8,467
   
Other (income) expense, net (763) 481
   
Interest (income) expense, net 4,248 6,040
   
Income tax expense 5,937 6,159
   
Acquisition-related charges 640 1,924
   
Employee termination and related costs -- 196
   
Intangible asset impairment charges 797 --
   
Charges associated with discontinued or withdrawn
 product lines
-- 246
   
Systems implementation charges 548 --
   
Facility consolidation, manufacturing and
 distribution transfer charges
236 189
   
Total of non-GAAP adjustments 20,369 23,702
   
Adjusted EBITDA $35,526 $34,927
   
Stock-based compensation 3,677 3,971
   
Adjusted EBITDA excluding stock-based compensation $39,203 $38,898
   
  
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
RECONCILIATION OF NON-GAAP ADJUSTMENTS – GAAP NET INCOME TO MEASURES OF ADJUSTED NET INCOME
AND ADJUSTED EARNINGS PER SHARE
(UNAUDITED)
 
(In thousands, except per share amounts) 
  Three Months Ended
June 30,
  2010 2009
   
GAAP net income $15,157 $11,225
Non-GAAP adjustments:  
   
Acquisition-related charges 640 1,924
   
Employee termination and related costs -- 196
   
Intangible asset impairment charges 797 --
   
Charges associated with discontinued or withdrawn
 product lines
-- 246
   
Systems implementation charges 548 --
   
Facility consolidation, manufacturing and
 distribution transfer charges
236 189
   
Loss related to early extinguishment of
 convertible notes
-- 89
   
Non-cash interest expense related to the
 implementation of FSP APB 14-1
1,888 2,765
   
Intangible asset amortization expense 4,211 4,866
   
Income tax expense related to above adjustments,
 quarterly adjustments to income tax expense
 related to the cumulative impact of changes in
 estimated tax rates and certain infrequently
occurring items that affected the reported tax rate
(2,593) (3,175)
   
 Total of non-GAAP adjustments 5,727 7,100
   
Adjusted net income $20,884 $18,325
   
Adjusted diluted net income per share * $0.68 $0.62
   
Weighted average common shares outstanding for
 diluted net income per share
30,399 29,202
   
* The calculation of earnings per share for common stock shown above excludes the income attributable to the unvested restricted share units from the numerator and excludes the dilutive impact of those units from the denominator.  The authoritative guidance had an insignificant impact ($0.01 or less per share) on diluted net income per share for both periods.  
   
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
CONDENSED BALANCE SHEET DATA
(UNAUDITED)
  
   
(In thousands)  
 
 
June 30, December 31,
  2010 2009
   
 Cash and cash equivalents $93,618 $71,891
 Accounts receivable, net 97,779 103,228
 Inventory, net 143,253 140,240
   
 Bank line of credit 220,000 160,000
 Convertible securities 151,900 225,514
   
 Stockholders' equity 460,376 444,885
  
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
RECONCILIATION OF NON-GAAP ADJUSTMENTS – GUIDANCE
 
  
 (In thousands, except per share amounts) 
  Projected Year Ended
  December 31, 2010
  Low High
GAAP net income $58,460 $63,160
   
Non-GAAP adjustments:  
   
Acquisition-related charges 1,720 1,720
   
Employee termination and related charges 720 720
   
Intangible asset impairment charges 800 800
   
Charges associated with discontinued or withdrawn
 product lines
70 70
   
Systems implementation charges 3,310 3,310
   
Facility consolidation, manufacturing
 and distribution transfer charges
2,040 2,040
   
Non-cash interest expense related to 
 the application of FSP APB 14-1
7,120 7,120
   
Intangible asset amortization expense 17,050 17,050
   
Income tax expense related
 to above adjustments
(11,990) (11,990)
   
Total of non-GAAP adjustments 20,840 20,840
   
Adjusted net income $79,300 $84,000
   
GAAP diluted net income per share $1.92 $2.07
   
Non-GAAP adjustments detailed above
 (per share)
$0.68 $0.68
   
Adjusted diluted net income per share $2.60 $2.75
   
Weighted average common shares
 outstanding for diluted net
 income per share
30,500 30,500
   

IART-F

CONTACT:  Integra LifeSciences Holdings Corporation
          John B. Henneman, III, Executive Vice President,
           Finance and Administration, and Chief Financial Officer
            (609) 275-0500
            jack.henneman@integralife.com
          Investor Relations:
          Angela Steinway 
            (609) 936-2268
            angela.steinway@integralife.com

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.